2 citations
,
March 2015 in “Hepatitis Monthly” This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.
6 citations
,
October 2016 in “Journal of Chemotherapy” This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.
January 2014 in “대한피부과학회지” This case study in a hepatitis B patient observed that pegylated interferon alpha2a treatment may induce localized alopecia areata, which appeared to correlate with treatment administration and discontinuation.
1 citations
,
January 2014 in “Hair therapy & transplantation” This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.
39 citations
,
January 2008 in “World Journal of Gastroenterology” This report documents the first known case of acute inflammatory demyelinating polyneuropathy potentially linked to pegylated interferon-alpha 2a in a woman undergoing treatment for chronic hepatitis C.
November 2022 in “JAAD case reports” This report diagnosed a 68-year-old man with comedonal folliculotropic mycosis fungoides based on clinical and histopathological findings, and found pegylated interferon alpha-2a with isotretinoin beneficial in reducing skin lesions.
41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.
176 citations
,
June 2016 in “PLoS ONE” In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.
9 citations
,
November 2012 in “Hepatology Research” This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.
2 citations
,
January 2007 in “Acta Dermato Venereologica” In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.
10 citations
,
September 2014 in “European Journal of Dermatology” This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.
3 citations
,
March 2014 in “Annals of Hepatology” This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.
26 citations
,
June 2005 in “Journal of The American Academy of Dermatology” In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.
32 citations
,
October 2004 in “Pharmacotherapy” In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.
34 citations
,
August 2002 in “British Journal of Dermatology” This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.
27 citations
,
April 2005 in “Journal of Chemotherapy” This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
107 citations
,
December 2003 in “Dermatologic Therapy” This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.
4 citations
,
January 2024 in “Scientific Reports” In this study, researchers examined chronic hepatitis B patients and found that those undergoing interferon therapy reported higher quality of life than those on non-antiviral or nucleoside/nucleotide analogue treatments, despite potential side effects.
This chapter reviews the structure, pharmacokinetics, and clinical applications of PEGylated liposomes and reports no new research findings.
34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.
9 citations
,
October 2018 in “Elsevier eBooks” This article discusses how challenges in drug development and success rates are driving a shift in the pharmaceutical industry towards engineering targeted drug delivery systems, with nanomaterials offering potential solutions for selective therapeutic delivery.
27 citations
,
August 2010 in “Clinics in Dermatology” This article reviews the association between hepatitis C virus and systemic disorders like mixed cryoglobulinemia, highlighting potential autoimmune side effects from interferon-a2b treatments, and reports no new clinical results.
July 2018 in “Elsevier eBooks” This study reviews drug-induced hair changes, noting that hair loss often reverses after stopping the drug, but permanent alopecia cases post-chemotherapy are rising.
25 citations
,
March 2019 in “Dermatologic therapy” This study reviewed the current state of intralesional therapy for keratoacanthoma, finding that while methotrexate, 5-fluorouracil, and interferon alpha are common agents, guidelines are still needed, and histopathological confirmation is advised to prevent misdiagnosis with squamous cell carcinoma.
March 2016 in “International Journal of Infectious Diseases” This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.
64 citations
,
January 2009 in “Canadian Journal of Gastroenterology” This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.
The researchers reported that PEG-FGF2 conjugates, particularly Compound 6, significantly enhanced stability, proliferation, migration, and wound healing activity compared to native FGF2, despite some reduction in bioactivity near crucial binding domains.
22 citations
,
September 2015 in “Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia” This review describes the various cutaneous manifestations of essential thrombocythemia and how treatments like hydroxycarbamide, interferon-alfa, and anagrelide may lead to skin complications, but does not report new clinical findings.